Search

Después de recibir tratamiento para el cáncer de recto, Roxanne Joseph ha vuelto a disfrutar de una vida activa junto a su marido, Rory, y sus dos hijos. Una investigación reciente realizada por Henry Walch, biólogo computacional del MSK, está arrojando luz sobre por qué el cáncer colorrectal ha sido más difícil de tratar en muchas personas de raza negra.

… Saturday, July 1, 2023 Por Jim Stallard Al principio, Roxanne Joseph pensó que estaba exagerando con las pesas en el gimnasio. La oficial de policía de Brooklyn estaba en óptimas condiciones físicas a los 41 años y se sentía muy bien. Pero después de notar sangre en sus heces, recordó el diagnóstico

A new immunotherapy approach involves engineering CAR T cells to produce proteins that treat lymphoma.

… Thursday, September 29, 2016 Summary Researchers have modified CAR T cells to produce a protein called HVEM that could treat lymphoma . When injected, the cells naturally zero in on the location of the cancer cells and churn out HVEM continuously for several days. This new immunotherapy approach could

Meet Tiffany Traina, a breast medical oncologist and the Vice Chair of the Department of Medicine at Memorial Sloan Kettering.

… Friday, April 2, 2021 Summary Tiffany A. Traina, MD , is Vice Chair of the Department of Medicine and has been a medical oncologist on the Breast Medicine Service since 2006. She is also the Section Head of the Triple Negative Breast Cancer Clinical Research Program in which she works to develop new

Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care.

… Thursday, June 14, 2018 Unlike the clinical management of other types of cancer, a multidisciplinary approach is not the established norm for treating skin cancer, resulting in significantly limited opportunities to individualize patient care. A recent study by our group, and set to be published in the

Memorial Sloan Kettering's new chief nurse Tracy Gosselin says she was taken by surprise when she was asked to consider MSK's top nursing job.

… Thursday, May 5, 2022 Tracy Gosselin says she was taken by surprise when she got the call asking her to consider applying for the top nursing job at Memorial Sloan Kettering Cancer Center (MSK).  “I laughed and said, ‘I can give you lots of names,’ ” she recalls. After careful thought and consultation

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, February 29, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Yael David Awarded 2024 Alfred P. Sloan Research Fellowship Yael David Yael David, PhD ,  chemical biologist leading  The Yael David Lab  and   Associate Member of the  Chemical

MSK researchers are making important inroads in understanding and treating pancreatic cancer.

… Saturday, January 1, 2022 For Barbara Brigham, being diagnosed with pancreatic cancer in the fall of 2020 was a devastating blow in an already rough year. She had just lost her mother and husband after long illnesses, both needing extensive care. The 74-year-old semiretired librarian from Long Island

Targeting this signal with drugs might be one way to stop cancers from spreading.

… Thursday, July 26, 2018 Summary Scientists from the Sloan Kettering Institute have identified a key step in the process of metastasis, how cancer spreads to other parts of the body. The step is shared across tumor types and suggests a new angle for targeted therapy. In 90% of cancer deaths, what kills

MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials.

… Monday, September 13, 2021 MSK physicians and researchers design and conduct clinical trials that include adolescent and young adult (AYA) cancer patients, ensuring they are not lost between the typical siloes of adult and pediatric cancer trials. As a result, more AYA patients benefit from an increasing

The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic mutation called a TRK fusion. Today’s decision marks a transformation in the field of precision medicine as this is the first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval, meaning that the drug was approved based on mutation type rather than on where in the body the tumor originated.

… Monday, November 26, 2018 Bottom Line VIDEO | 02:42 Rihanna's Story of Treatment on a Clinical Trial with Larotrectinib Meet Rihanna, who was on a clinical trial with larotrectinib. Video Details The US Food and Drug Administration (FDA) has approved the drug larotrectinib for cancers caused by a genetic